가톨릭대학교 산학협력단;CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION;CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATIONFOUNDATION
发明人:
CHO, MI LA,조미라,PARK, MI KYUNG,박미경,LEE, SEON YEONG,이선영,HER, YANG MI,허양미,PARK, JIN SIL,박진실,MUN, YEONG MI,문영미,LIM, MI AE,임미애,JEONG, JEONG HEE,정정희
申请号：
KR1020130028183
公开号：
KR1020130105545A
申请日:
2013.03.15
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
PURPOSE: An ROR alpha is provided to suppress the activation of Th17 cells and to regulate immune response, thereby effectively treating and preventing various allergic diseases or autoimmune diseases. CONSTITUTION: A method for reducing the activation of Th17 cells comprises the step of promoting the expression or activation of ROR alpha by transducing a recombinant expression vector containing ROR alpha genes into Th17 cells. ROR alpha gene has a sequence of sequence number 11 or 12. The recombinant expression vector contains a promoter or an enhancer which promotes the expression or activation of ROR alpha. A composition for preventing and treating Th17 cell activation-related diseases contains an agent for promoting the expression or activation of ROR alpha； or Th17 cells in which the agent is transduced, as an active ingredient.본 발명은 RORα(레티노산 결합 수용체α)-Th17(T helper type 17) 간의 상호작용 및 그 이용에 관한 것으로, 보다 구체적으로 RORα-Th17 간의 상호작용 및 이와 관련된 분자적 메커니즘을 이용한 면역 조절 방법 및 이를 이용한 세포치료제 개발에 관한 것이다.
